Diagnostic Value of the Texture Analysis Parameters of Retroperitoneal Residual Masses on Computed Tomographic Scan after Chemotherapy in Non-Seminomatous Germ Cell Tumors.
non-seminomatous germ cell tumor
prediction
radiomics
residual lesions
score
surgery
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
21
04
2023
revised:
25
05
2023
accepted:
29
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
After chemotherapy, patients with non-seminomatous germ cell tumors (NSGCTs) with residual masses >1 cm on computed tomography (CT) undergo surgery. However, in approximately 50% of cases, these masses only consist of necrosis/fibrosis. We aimed to develop a radiomics score to predict the malignant character of residual masses to avoid surgical overtreatment. Patients with NSGCTs who underwent surgery for residual masses between September 2007 and July 2020 were retrospectively identified from a unicenter database. Residual masses were delineated on post-chemotherapy contrast-enhanced CT scans. Tumor textures were obtained using the free software LifeX. We constructed a radiomics score using a penalized logistic regression model in a training dataset, and evaluated its performance on a test dataset. We included 76 patients, with 149 residual masses; 97 masses were malignant (65%). In the training dataset (
Identifiants
pubmed: 37296963
pii: cancers15112997
doi: 10.3390/cancers15112997
pmc: PMC10252126
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Pers Med. 2021 Aug 27;11(9):
pubmed: 34575619
J Clin Oncol. 1998 Jan;16(1):269-74
pubmed: 9440752
Stat Med. 2001 Dec 30;20(24):3847-59
pubmed: 11782038
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Stat Med. 2007 Dec 30;26(30):5512-28
pubmed: 18058845
J Clin Oncol. 2008 Dec 20;26(36):5930-5
pubmed: 19018083
Eur Radiol. 2020 Apr;30(4):2334-2345
pubmed: 31828413
Invest Radiol. 2021 Mar 1;56(3):173-180
pubmed: 32932375
Clin Cancer Res. 2017 Nov 15;23(22):6904-6911
pubmed: 28874414
Urol Oncol. 2014 Jan;32(1):33.e1-6
pubmed: 23395239
Ann Oncol. 1990 Jul;1(4):281-8
pubmed: 1702312
Eur Urol. 2008 Mar;53(3):497-513
pubmed: 18191015
Ann Oncol. 2018 Aug 1;29(8):1658-1686
pubmed: 30113631
Ann Oncol. 2017 Feb 1;28(2):362-367
pubmed: 27831507
Magn Reson Imaging. 2004 Jan;22(1):81-91
pubmed: 14972397
Eur Urol. 2012 Feb;61(2):403-9
pubmed: 22078334
Urol Oncol. 2019 Nov;37(11):809.e9-809.e18
pubmed: 31540832
J Pers Med. 2022 Mar 31;12(4):
pubmed: 35455668
J Clin Oncol. 2016 Jun 20;34(18):2157-64
pubmed: 27138577
Urol Oncol. 2018 Feb;36(2):82.e1-82.e5
pubmed: 29129354
Bull Cancer. 2020 Feb;107(2):215-223
pubmed: 31882267
Prog Urol. 2018 Nov;28 Suppl 1:R149-R166
pubmed: 31610870
Eur Urol Focus. 2018 Dec;4(6):995-1001
pubmed: 29428550
Radiother Oncol. 2019 Jun;135:153-160
pubmed: 31015162
Rev Prat. 2007 Feb 28;57(4):389-98
pubmed: 17455741
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):292-298
pubmed: 29726358
Eur Urol. 2007 Feb;51(2):424-32
pubmed: 16911854
Urol Clin North Am. 2015 Aug;42(3):331-42
pubmed: 26216820
Prog Urol. 2020 Nov;30(12S):S136-S251
pubmed: 33349424
Eur Urol. 1996;29(3):325-30
pubmed: 8740018
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Acta Radiol. 2016 Jun;57(6):669-76
pubmed: 26271125
Eur Radiol. 2019 Jan;29(1):392-400
pubmed: 29922924
J Urol. 2004 May;171(5):1835-8
pubmed: 15076288
J Urol. 2018 Jul;200(1):126-135
pubmed: 29474847
Int J Urol. 2015 Jul;22(7):663-8
pubmed: 25847721
Eur Radiol. 2015 Feb;25(2):480-7
pubmed: 25216770
JCO Clin Cancer Inform. 2018 Dec;2:1-12
pubmed: 30652572
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929